Sign In
Buy SRRK
$36.47
-0.94 (-2.51%)
At Close: Nov 17, 2025
Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript
02:01pm, Friday, 14'th Nov 2025
Scholar Rock Holding Corporation ( SRRK ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Laura Ekas David Hallal - CEO & Chairman of the Board Akshay Vaishnaw - President of
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Friday, 14'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 12'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common
3 Beaten-Down Stocks With Rebound Potential This Earnings Season
08:15am, Wednesday, 12'th Nov 2025
Earnings season often shines a spotlight on well-known mega-caps, but it can also bring opportunities for lesser-known companies to shine. Below are three stocks—each down significantly in 2025—th
Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)
11:28am, Monday, 10'th Nov 2025
Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achiev
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
08:00am, Thursday, 23'rd Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 17'th Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults
Insiders Bet Big on These 3 Fintech and Biotech Stocks
08:45am, Friday, 17'th Oct 2025
The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.
Why Scholar Rock Stock Got Socked on Monday
05:22pm, Monday, 13'th Oct 2025
A potential delay in an important submission was the news item driving Scholar Rock's (SRRK -13.14%) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more than
Why Scholar Rock Stock Raced 6% Higher Today
05:07pm, Thursday, 09'th Oct 2025
An analyst's initiation of coverage was the spark that lit the fire underneath Scholar Rock's (SRRK 5.95%) equity on Thursday. The clinical-stage biotech's share price ballooned by 6% in response, on
Wall Street Insiders Are Loading Up on These 3 Stocks
02:34pm, Wednesday, 08'th Oct 2025
People don't like to throw money into a sinking ship , and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do in the coming quarters.
Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions
05:02pm, Tuesday, 23'rd Sep 2025
Scholar Rock Holding Corporation remains a Strong Buy despite a recent FDA Complete Response Letter for apitegromab in spinal muscular atrophy. The CRL was due to manufacturing site issues with Catale
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
11:32am, Tuesday, 23'rd Sep 2025
The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA)
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
10:02am, Tuesday, 23'rd Sep 2025
Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant.
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
08:16am, Tuesday, 23'rd Sep 2025
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Tuesday.
